KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $613000.0.

  • Aurinia Pharmaceuticals' Gains from Investment Securities fell 7955.99% to $613000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year decrease of 8118.97%. This contributed to the annual value of $12.0 million for FY2024, which is 8725.3% down from last year.
  • Aurinia Pharmaceuticals' Gains from Investment Securities amounted to $613000.0 in Q3 2025, which was down 7955.99% from $6.2 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $90.7 million during Q4 2023, with a 5-year trough of -$1.4 million in Q1 2022.
  • Its 5-year average for Gains from Investment Securities is $8.1 million, with a median of $3.0 million in 2022.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 12367.33% in 2022, then surged by 779016.54% in 2023.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Gains from Investment Securities stood at $5.8 million in 2021, then tumbled by 80.2% to $1.1 million in 2022, then surged by 7790.17% to $90.7 million in 2023, then plummeted by 96.69% to $3.0 million in 2024, then plummeted by 79.57% to $613000.0 in 2025.
  • Its last three reported values are $613000.0 in Q3 2025, $6.2 million for Q2 2025, and $8.9 million during Q1 2025.